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Matrix metalloproteinases (MMPs) are a major group of enzymes that regulate cell–matrix composition. 
The MMPs are zinc-dependent endopeptidases known for their ability to cleave one or several 
extracellular matrix (ECM) constituents, as well as nonmatrix proteins. This review focuses on structural 
and functional elements of MMPs, and their roles in physiological and pathological processes, in which 
it is believed the MMPs play an important, or even indispensable role. According to their structural and 
functional characteristics, MMP family members have been classified into six different but closely 
related subgroups with fairly characteristic but often overlapping substrate specificities. MMP 
synthesis and functions are regulated by transcriptional activation, post-transcriptional processing 
(release of pro-domain, cell surface shedding), and control of activity by a family of endogenous 
inhibitors collectively known as tissue inhibitors of metalloproteinases (TIMPs). The balance of MMPs 
to TIMPs therefore determines matrix turnover, where either an excess of MMPs or a deficit of TIMPs 
may result in excess ECM degradation. Moreover, the recent development of selective and non-
selective inhibitors of MMPs would also provide new insights in the knowledge of the relationship 
between activation of inflammatory cells and tissue remodeling and propose new therapeutic 
possibilities to the treatment of inflammatory disease. 
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INTRODUCTION 
 
Modulation of cell–matrix interactions occurs through the 
action of unique proteolytic systems responsible for 
hydrolysis of a variety of extracellular matrix (ECM) 
components. By regulating the integrity and composition 
of the ECM structure, these enzyme systems play a 
pivotal role in the control of signals elicited by matrix 
molecules, which regulate cell proliferation, differentia-
tion, and cell death. The turnover and remodeling of ECM 
must be highly regulated, since uncontrolled proteolysis 
contributes to abnormal development and to the genera-
tion of many pathological conditions characterized by 
either excessive degradation or a lack of degradation of 
ECM components. Matrix metalloproteinases (MMPs) are 
a major group of enzymes that regulate cell–matrix 
composition. The MMPs are zinc-dependent endopepti-
dases known for their ability to cleave one or several 
ECM constituents,  as  well  as  nonmatrix  proteins. They 
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comprise a large family of proteases that share common 
structural and functional elements and are products of 
different genes. The first report of an enzyme from verte-
brate (as opposed to bacterial) sources that was capable 
of attacking the triple helix of native type I collagen was 
published by Gross and Lapiere (1962). In this report, 
they demonstrated that the enzyme activity, secreted by 
cultured tissue fragments of tail fin skin from resorbing 
tadpole tails in metamorphosis, was true collagenase 
acting on collagen at 27°C at neutral pH (Vu et al., 2000). 
The reason for this interest on MMPs is pointed out 
most clearly by Table 1, which shows some of the points 
of involvement of the MMPs in normal biologic and 
pathologic processes. Embryonic growth and tissue 
morphogenesis are fundamental events that require disruption 
of ECM barriers to allow cell migration and micro-
environmental matrix remodeling. The ability of MMPs to 
degrade structural components of ECM and BM has 
supported their direct roles in these processes (Vu et al., 
2000). Although the main function of MMPs is removal of 
ECM during  tissue  resorption  and  progression of many
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Table 1. Involvement of the MMPs in normal and pathological processes (Parks and Mecham, 1998).  
 
Normal and pathological processes in which MMPs are implicated 
Normal  Pathological 
Development Reproduction Maintenance  Tissue destruction Fibrotic diseases Weakening of matrix 
Blastocyst implantation Endometrial cycling Remodeling of bone  Rheumatoid arthritis Liver cirrhosis Dilated cardiomyopathy 
Embryonic development Graafian follicle rupture Hair follicle cycle  Osteoarthritis Fibrotic lung disease Epidermolysis bullosa 
Nerve growth Luteolysis Wound healing  Cancer invasion Otosclerosis Aortic aneurysm 
Growth plate cartilage removal Cervical dilatation Angiogenesis  Cancer metastasis Atherosclerosis  
Skeletal, bone growth Postpartum uterine involution Apoptosis  Decubitus ulcer Multiple sclerosis  
Nerve outgrowth Mammary gland morphogenesis Nerve regeneration  Gastric ulcer   
Enamel maturation Mammary gland involution Macrophage function  Corneal ulceration   
Primary tooth resorption Rupture of fetal membranes Neutrophil function  Periodontal disease   
 
 
 
diseases, it is notable that MMPs also alter 
biological functions of ECM macromolecules by 
specific proteolysis. Most MMP genes are highly 
expressed in a number of reproductive processes, 
including menstrual cycle, ovulation and uterine, 
breast and prostate involution (Curry and Osteen, 
2003). 
MMPs are also involved in wound healing, a 
tissue-remodeling process which involves the 
migration of keratinocytes at the edge of the 
wound to re-epithelialize the damaged surface. 
The role of MMPs in angiogenesis is also wide 
and complex. Many MMPs are produced by 
endothelial cells and have been described to be 
important for the formation of new blood vessels 
in both physiological and pathological conditions. 
MMPs are considered to participate in dissemina-
tion of cancer cells by breaking down ECM, but 
they are also important in creating an environment 
that supports the initiation and maintenance of 
growth of primary and metastatic tumors 
(Chambers and Matrisian, 1997). MMPs have 
recently been found also in pulpal tissue and 
odontoblasts, where they play a role in dentin 
matrix formation and modulation during caries 
progression    and   secondary   dentin    formation 
(Tjäderhane et al., 1998). 
 
 
DOMAIN STRUCTURE AND FUNCTION 
 
If one examines the MMPs starting from the N 
terminus, the following features are seen: 1) 
signal peptide, 2) propeptide, 3) furin-cleavage 
site insert, 4) catalytic domain, 5) fibronectin-like 
repeats, 6) hinge region, 7) hemopexin domain, 
and 8) membrane insertion extension (Figure 1) 
(Massova et al., 1998). 
 
Signal peptide: It is typically a stretch of 17 to 20 
residues, rich in hydrophobic amino acids, that 
serves as a signal for secretion into the endoplas-
mic reticulum for eventual export from the cell. 
 
Propeptide domain: It consists of approximately 
80 to 90 amino acids containing a cysteine 
residue, which interacts with the catalytic zinc 
atom via its side chain thiol group. A highly 
conserved sequence (. . .PRCGXPD. . .) is 
present in the propeptide. Removal of the propep-
tide by proteolysis results in proenzyme activation, 
as all members of the MMPs family  are  produced 
in a latent form. The Cys within this sequence (the 
“cysteine switch”) ligates the catalytic zinc to 
maintain the latency of pro-MMPs (Borden and 
Heller, 1997). This cysteine is found in all MMPs, 
including those that have the furin-cleavage site. 
 
Furin-cleavage site insert: This stretch of about 
nine residues includes the consensus sequence 
of RXKR/RRKR that leads to intracellular 
cleavage by furin. MMP-11, -14,-15, -16, and-17 
possess this sequence. In the remaining 
enzymes, a cleavage by external proteases 
occurs in the middle of the propeptide, partially 
exposing the zinc and leading to autolytic 
cleavage of the remainder of the propeptide. The 
exact site of final cleavage may vary within a 
given enzyme leading to different degrees of 
activation, particularly in the case of MMP-1. 
 
The catalytic domain (about 170 amino acids): 
It contains two zinc ions and at least one calcium 
ion coordinated to various residues. One of the 
two zinc ions is present in the active site and is 
involved in the catalytic processes of the MMPs. 
The catalytic zinc ion is essential for the 
proteolytic  activity  of  MMPs;  the  three  histidine
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Figure 1. Representation of a prototype matrix metalloproteinase. All the interstitial collagenases 
contain variations of the domains indicated in this representation (Birkedal-Hansen et al., 1993).  
 
 
 
residues that coordinate with the catalytic zinc are 
conserved among all the MMPs. The 50 to 54 residues at 
the C-terminal end of the catalytic domain include the site 
of binding of the catalytic zinc. Little is known about the 
roles of the second zinc ion and the calcium ion within the 
catalytic domain, but the MMPs are shown to possess 
high affinities for structural zinc and calcium ions (Bode et 
al., 1994). 
 
Fibronectin-like repeats: These specialized structures 
aid the binding of enzyme to gelatin and collagen 
substrates (Steffensen et al., 1995).  
 
Hinge region: The catalytic domain is connected to the 
following hemopexin domain by a linker region usually 
referred to as the hinge region. It ranges in length from 0 
to 75 residues. The longest hinge is found in MMP-9 and 
shows considerable homology to type V collagen in that it 
is rich in proline. A typical hinge contains about 16 
residues including a number of proline residues (Pendas 
et al., 1997). 
 
The hemopexin-like domain (about 210 amino acid) of 
MMPs: It is highly conserved and shows sequence 
similarity to the plasma protein, hemopexin. The 
hemopexin-like domain has been shown to play a 
functional role in substrate binding and/or in interactions 
with the TIMPs, a family of specific MMP protein 
inhibitors (Gomis-Rüth et al., 1997). The hemopexin 
domain is an absolute requirement for collagenases to 
cleave triple helical interstitial collagens (Bode, 1995), 
although the catalytic domains alone retain proteolytic 
activity toward other substrates.  
 
Membrane insertion extension: Although most MMPs 
have their C terminus at the end of the hemopexin 
domain, the four MT-MMPs have a further extension that 
governs   insertion   of   these   proteases   into   the  cell 
membrane. Its length ranges from about 80 to 110 
residues. 
 
 
Classification of MMPs 
 
There are now at least 18 distinct vertebrate MMPs 
(Barrett et al., 1998). They were first described in 
vertebrates (Gross and Lapiere, 1962) including humans, 
but have since been found in invertebrates and plants. 
They are distinguished from other endopeptidases by 
their dependence on metal ions as cofactors, their ability 
to degrade extracellular matrix, and their specific 
evolutionary DNA sequence. Table 2 lists the currently 
known MMPs and related forms from lower organisms. 
The MMPs share high protein sequence homology and 
have defined domain structures and thus, according to 
their structural properties, the MMPs are classified as 
either secreted MMPs or membrane anchored MMPs, 
which are further divided into eight discrete subgroups: 
five are secreted and three are membrane-type MMPs 
(MT-MMPs) (Heikkilä, 2005). 
According to their structural and functional character-
ristics, MMPs family members have been classified into 
different but closely related subgroups with fairly 
characteristic but often overlapping substrate specifici-
ties. This classification considers collagenases (MMP-1, 
8, 13 and 18), gelatinases (MMP-2 and 9), stromelysins 
(MMP-3, 10, 11), elastases (MMP-7 and 12), and 
membrane type MMPs (MT-MMPs, MMP-14, 15, 16 and 
17) and a group of unnamed members (Massova et al., 
1998). In addition to a remarkably common 3-D structure 
(Vu et al., 2000), MMPs share a similar gene 
arrangement, suggesting that they arose by duplications 
of an ancestor gene. At least eight of the known human 
MMPs genes (MMP-1, -3, -7, -8, -10, -12, -13 and -20) 
are clustered on chromosome 11 at 11q21-23. Other 
MMP genes are scattered  among chromosomes 1, 8, 12,
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Table 2. MMP (Clark, 2001). 
 
MMP-No. Name E.C. number Other names/notes 
MMP-1 Collagenase 1 3.4.24.7 Interstititial collagenase 
MMP-2 Gelatinase A 3.4.24.24 72 kDa gel’ase, type IV collagenase 
MMP-3 Stromelysin 1 3.4.24.17 Transin,proteoglycanase,CAP 
(MMP-4 Procollagen peptidase _ Discontinued = MMP-3) 
(MMP-5 3/4-Collagenase _ Discontinued = MMP-2) 
(MMP-6 Acid metalloprotease _ Discontinued = MMP-3) 
MMP-7 Matrilysin 3.4.24.23 Pump-1 
MMP-8 Collagenase 2 3.4.24.34 Neutrophil collagenase 
MMP-9 Gelatinase B 3.4.24.35 92 kDa gel’ase, type V collagenase 
MMP-10 Stromelysin 2 3.4.24.22 Transin 2 
MMP-11 Stromelysin 3  Furin motif 
MMP-12 Macrophage elastase 3.4.24.65 Metalloelastase 
MMP-13 Collagenase 3  Rodent intersititial collagenase 
MMP-14 Membrane type matrix metalloproteinase 1  MT1-MMP, furin motif 
MMP-15 Membrane type matrix metalloproteinase 2  MT2-MMP, furin motif 
MMP-16 Membrane type matrix metalloproteinase 3  MT3-MMP, furin motif 
MMP-17 Membrane type matrix metalloproteinase 4  MT4-MMP, furin motif 
MMP-18 Collagenase 4  Xenopus 
MMP-19 No trivial name  RASI-1 
MMP-20 Enamelysin   
XMMP No trivial name  Xenopus, furin motif 
MMP-C31 (also H19, Y19)  Caenorhabditis elegans 
_ Envelysin 3.4.24.12 Sea urchin 
_ Soybean MMP  Glycine max, no cDNA 
_ Fragilysin 3.4.24.74 Bacteroides fragilis 
 
 
 
14, 16, 18, 20, and 22 (Shapiro, 1998). 
 
 
A BRIEF OVERVIEW OF THE INDIVIDUAL 
INTERSTITIAL COLLAGENASES 
 
The role of all the factors participating in the spread of 
inflammation and necrosis in pulp tissue is not completely 
understood. Since MMPs, the host enzymes responsible 
for the extracellular matrix degradation, have been 
suggested to be important in other inflammatory condi-
tions such as periodontitis, it is possible that they also 
participate in the pathogenesis of pulp and periapical 
inflammation. The area of interstitial collagenase chemi-
stry and biology, in parallel with that of the matrix 
metalloproteinases in general, has undergone explosive 
growth. These enzymes are known to be effective in 
various inflammatory and other tissue destructive 
diseases. Collagenases are actively taking part in the 
tissue destruction and granulation tissue formation in 
chronic apical periodontitis (Wahlgren, 2003). Collage-
nase-1 (MMP-1), collagenase-2 (MMP-8) and 
collagenase-3 (MMP-13) comprise the collagenase 
subfamily capable of initiating degradation of native fibrillar 
collagen types I, II, III, V and  IX  (Knäuper  et  al.,  1996). 
Collagenases can also digest a number of other ECM 
and non-ECM molecules.  
The collagenases differ in their substrate specificities 
and functional roles. MMP-1 preferably degrades 
collagen III, MMP-8 prefers type I collagen, and MMP-13 
prefers collagen II (Massova et al., 1998; Knäuper et al., 
1996). MMP-1 is the most often associated collagenase 
with normal tissue remodeling. MMP-1 is expressed by 
fibroblasts, endothelial cells, macrophages, 
hepatocytes,chondrocytes, osteoblasts, odontoclasts, 
tumors cells and migrating epidermal keratinocytes and 
its expression can be induced in certain inflammatory 
diseases and cancers (Giambernardi et al., 1998).  
The MMP-1 gene is localized on chromosome 11q22 
(Brinckerhoff et al., 2000). It is constitutively expressed at 
low levels under normal physiological conditions; 
however, its expression may increase markedly in 
pathological conditions. MMP-1 is present in jaw cyst wall 
extracts and cyst fluids (Teronen et al., 1995). MMP-8 
was first cloned from messenger RNA (mRNA) extracted 
from the peripheral leucocytes of a patient with chronic 
granulocytic leukemia (Hasty et al., 1990). MMP-8 is 
synthesized in polymorphonuclear leukocytes during their 
maturation in bone marrow and stored in specific 
intracellular granules, out of  which  it  is  secreted  to  the 
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Table 3. Tissue inhibitors of metalloproteinases (TIMPs) (Clark, 2001). 
 
Family member Reported functions 
TIMP-1 Inhibition of all known MMP family members. Associates with proMMP-9. Inhibits angiogenesis. Erythroid-potentiating activity. 
  
TIMP-2 Inhibitions all known MMP family members. Associates with MT1-MMP and MMP-2 at cell surface and 
regulates MMP-2 activation. 
  
TIMP-3 Inhibition of all known MMP family members. Extracellular matrix-associated. Mutation associated with Sorsby’s fundus dystrophy. 
  
TIMP-4 Inhibition of all known MMP family members. Restricted expression suggests tissue specific TIMP function. 
 
 
 
cell environment in response to external triggering stimuli 
and the enzyme thus plays a key role in tissue 
destruction during inflammatory diseases (Ding et al., 
1997). The presence of MMP-8 in healthy odontoblasts 
and pulp tissue suggests that MMP-8, an efficient inducer 
of type I collagenolysis, may contribute to the modulation 
of dentin and secondary dentin formation (Wahlgren, 
2003). In pulpitis, the MMP-8 was expressed in various 
inflammatory cells, such as PMNs, macrophages, plasma 
cells and in endothelial cells. In pulpitis, MMP-8 was 
considered to originate from both PMN and non-PMN 
lineage cells. The main MMP-8 positivity was 
accumulated around the pulp abscess suggesting that it 
also contributes to the abscess formation (Wahlgren, 
2003). 
Monocytes/macrophages express MMP-8 and MMP- 
13, and these MMPs may work not only extracellulary, 
taking part in tissue destruction, but also intracellulary, in 
the phagocytic process (Knäuper et al., 1996). MMP-8 
can also be detected in mucosal fibroblasts, 
chondrocytes, odontoblasts, monocyte/macrophages, 
melanoma cells, leukaemia cells, malignant plasma cells 
and human endothelial cells (Kiili et al., 2002; Moilanen et 
al., 2003; Wahlgren et al., 2001). The major collagenase 
species detected in inflamed human periodontium is 
MMP-8 (Romanelli et al., 1999). MMP-8 is expressed in 
vivo by bronchial epithelial cells and macrophages 
involved in bronchiectasis, chondrocytes in rheumatoid 
arthritis and osteoarthritic lesions, rheumatoid synovial 
fibroblasts, in human gingival sulcular epithelial cells, in 
cells of human atheroma, in plasma cells associated with 
oral keratocysts and by cells in proliferating and migratory 
wound epithelia, in dermal fibroblasts and inflammatory 
cells (Tervahartiala et al., 2000). 
In vitro, MMP-8 is released out of leucocytes during the 
chemotactic stimulation and, in vivo, response to local 
inflammatory conditions (Tschesche, 1995). MMP-13 was 
originally cloned from human breast tumor cDNA library 
(Hasty et al., 1990). It has the widest substrate selection 
among the interstitial collagenases and, in addition to 
collagens, it is able to cleave various BM components. 
MMP-13 cleaves type II collagen more efficiently than 
types I and III, and among interstitial collagenases, it is 
most effective in cleaving gelatin (Ding et al., 1997). The 
physiological expression of MMP-13 seems to be limited 
only to developing bone (Kiili et al., 2002), wound healing 
and teeth (Moilanen et al., 2003). It is widely expressed in 
pathological conditions including rheumatoid arthritis, 
osteoarthritis, periodontitis, chronic ulcerations, hypertro-
phic chondrocytes, osteoblasts as well as plasma cells 
and many carcinoma and melanoma cells (Wahlgren et 
al., 2001; Knäuper et al., 1996; Romanelli et al., 1999). 
MMP-13 is predicted to have an important role in tumors 
invasion and metastasis due to its wide substrate-
specificity together with catalytic efficiency and its 
upregulated expression in cancer cells (Tervahartiala et 
al., 2000). 
Cleavage of type I collagen by MMP-1 and by MMP-13 
initiates keratinocyte migration during reepithelialization 
and osteoclast activation, respectively (Tschesche, 
1995). In the study of Andonovska et al. (2008), results 
from quantitative enzyme method demonstrated that the 
concentrations of collagenases (MMP-1, -8, -13) in 
chronic pulp inflammation were significantly higher than 
those of the control group (normal pulp tissue). In 
addition, concentrations of collagenases in patients with 
diagnosed periapical lesions were significantly higher 
than those  of  the control group and were higher from the  
patients with chronic pulp inflammation. 
 
 
Regulation of activity of MMPs 
 
The activity of MMPs is regulated at several different 
stages: transcriptional, post-transcriptional, controlled at 
the protein level via their activators, inhibitors, and/or cell 
surface location. MMPs levels are usually low in normal 
adult tissues, and with some exceptions, their production 
and activity are maintained at practically undetectable 
levels. The MMPs are tightly regulated, as they need to 
be present in the right cell type and pericellular location at 
the right time and in the right amount. A loss of activity 
control may result in diseases. Thus, MMPs are regulated 
at the transcriptional and post-transcriptional levels and 
their expression becomes elevated, when there is a 
challenge to the system, such as wound healing, repair or  
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remodeling processes, in diseased tissues, and even in 
several cell types grown in culture (Clark, 2001). 
MMPs are also regulated by activation of the precursor 
zymogens and inhibition by endogenous inhibitors, tissue 
inhibitors of metalloproteases (TIMPs). The extracellular 
activation of most MMPs is regulated by a proteolytic 
cascade and can be initiated by other already activated 
MMPs or by several serine proteases. The TIMPs are the 
main natural inhibitors of MMPs and, as such, they tightly 
control metalloproteases catalytic activity. Thus, the 
balance between MMPs and TIMPs is critical for the 
eventual ECM remodeling. Disruption of the balance 
between MMPs and TIMPs contributes to pathophysio-
logical processes, such as many chronic tissue 
destructive inflammatory and autoimmune diseases.  
Also, MMPs activity can be inhibited by the synthetic 
inhibitors. Synthetic inhibitors of MMP generally contain a 
chelating group which binds the catalytic zinc atom at the 
MMP active site tightly. Common chelating groups 
include hydroxamates, carboxylates, thiols, and 
phosphinyls. Hydroxymates are particulary potent 
inhibitors of MMPs and other zinc-dependent enzymes, 
due to their bidentate chelation of the zinc atom. Other 
substituents of the inhibitors are more or less specific for 
given MMPs (Meng et al., 2008). The transcriptional 
regulation of MMPs appears to represent the key step in 
MMPs regulation, since most MMPs genes are 
expressed only when active physiological or pathological 
tissue remodeling takes place (Matrisian, 1990). 
Overall, it is clear that the transcriptional regulation of 
MMPs production is a very complicated phenomenon 
including the regulation of the production and degradation 
of transcription factors and the regulation of their trans-
activating activities and via these processes the 
modulation of MMPs production in cells. Spontaneous 
sequence variations in the promoters of MMPs could 
influence critical steps in binding to transcription factors 
or overall transcriptional efficiency, which results in 
discrepancy in the expression  of MMPs in different 
individuals. In fact, genetic polymorphisms can alter the 
binding sites of some functional regulating factors and 
influence the level of MMPs expression (Arakaki et al., 
2009). 
 
 
Inhibition mechanism of TIMPs 
 
There are different mechanisms to inhibit or down-
regulate MMPs. Inhibition may take place by interaction 
with an active Zn2+-site or by cleaving the active enzyme 
or binding it to a non-active complex form. To influence 
the MMP levels, it is also possible to down-regulate 
MMPs at the transcriptional level (Birkedal-Hansen et al., 
1993). The proteolytic activity of the MMPs involved in 
extracellular matrix degradation must be precisely 
regulated by their endogenous protein inhibitors, the 
TIMPs. Disruption of this balance results in serious 
diseases.   TIMPs   (21   to   30   kDa)    are    the    major 
 
 
 
 
endogenous regulators of MMPs activities in the tissue, 
and four homologous TIMPs (TIMPs-1 to -4) have been 
identified to date (Table 3) (Matrisian, 1990). 
The TIMPs are secreted proteins, but may be found at 
the cell surface in association with membrane-bound 
proteins. TIMPs have effects on cell growth and survival 
that cannot always be clearly reconciled with their ability 
to abrogate MMPs activity. TIMP-1 was first identified as 
an agent that stimulates growth of some cell lines 
(Gasson et al., 1985). It was first noted by Bauer et al. 
(1975) that cultured human fibroblasts produced an 
inhibitory protein. TIMP-1 inhibits MMP-1, MMP-3 and 
MMP-9 more effectively than TIMP-2. TIMP-2 also has 
erythroid potentiating activity and stimulates the growth of 
lymphoma cells (Stetler-Stevenson et al., 1997) and 
fibroblasts. TIMP-2 protein has been detected around 
migrating keratinocytes in human wounds and is 
believed, at least partially, to be produced by these cells 
(Vaalamo et al., 1997). 
TIMP-2 inhibits proMMP-2 over 10-fold more effectively 
than TIMP-1. However, TIMP-2 has a bi-functional effect 
on MMP-2, since MT-MMP mediated proMMP-2 
activation requires a tiny amount of TIMP-2 to make 
activation progress, whereas a greater concentration of 
TIMP-2 inhibits MMP-2 (Brew et al., 2000). High levels of 
TIMP-3 promote apoptosis in many cell types in vitro and 
in vivo (Vaalamo et al., 1997), and this effect is 
associated with death receptor modulation. TIMP-3 
inhibits at least MMP-2 and MMP-9, whereas TIMP-4 is a 
good inhibitor for all classes of MMPs without remarkable 
preference for specific MMPs. Active MMP-13 is an 
example of an MMP, which is inhibited by all types of 
TIMPs (Palosaari, 2003). TIMP-4 can also instigate 
apoptosis in transformed cardiac fibroblasts but inhibits 
apoptosis in human breast cancer cells in vitro and 
mammary tumors in vivo; it is thus a tumor promoter 
when over expressed. TIMP-4 regulates MMP-2 activity 
both by inhibiting MT1-MMP and by inhibiting activated 
MMP-2 (Palosaari, 2003). 
While TIMPs usually inhibit already active MMP, 
gelatin-binding MMPs are an exception, since TIMP 
reversibly binds to the proforms of both MMP-2 and 
MMP-9. It is widely appreciated that TIMPs inhibit cell 
invasion in vitro, tumor genesis, metastasis in vivo, and 
angiogenesis. TIMPs exhibit additional biological 
functions. TIMP-1 and TIMP-2 have mitogenic activities 
on a number of cell types, whereas over expression of 
these inhibitors reduces tumor cell growth, and TIMP-2, 
but not TIMP-1, inhibits basic fibroblast growth factor-
induced human endothelial cell growth. These biological 
activities of TIMPs are independent of MMP-inhibitory 
activities. TIMPs are therefore important regulators not 
only in matrix turnover but also in cellular activities 
(Palosaari, 2003). 
 
 
SUMMARY AND FUTURE PROSPECTS 
 
In   recent   years,   MMPs  have    gained    considerable 
  
 
 
attention in many studies on normal tissue events, 
inflammation, and disease processes, and this enhanced 
interest is probably due to several factors. For the most 
part, MMPs are produced or activated when needed, and 
expression of these enzymes provides a reliable indicator 
of ongoing tissue remodeling. Thus, for investigators, 
these enzymes are models of gene products that are 
accurately regulated and precisely targeted to specific 
extracellular substrates by a wide variety of cells during 
numerous normal tissue processes, such as wound 
healing, bone resorption, and morphogenesis. In 
contrast, exuberant production of MMPs is a hallmark of 
many destructive diseases, such as arthritis and chronic 
ulcerations, and of many disease-related processes, such 
as inflammation, metastasis, and angiogenesis, and 
aberrant regulation of MMPs production is thought to be a 
primary mechanism contributing to disease progression 
and injury. 
As such, understanding how MMPs expression and 
activation are controlled and identifying which 
proteinases are produced by which cells under defined 
conditions will have a great impact on our understanding 
of normal biology and disease pathogenesis (Sorsa et al., 
2004). Several reports in recent years have demonstra-
ted that various MMPs act on non-matrix proteins, such 
as cytokines, chemokines, receptors and antimicrobial 
peptides (Sorsa et al., 2004). Thus, MMPs should not be 
viewed solely as proteinases for matrix catalysis, but 
rather as extracellular processing enzymes involved in 
regulating cell–cell and cell–matrix signaling events, 
typically gain-of-function processing of latent proteins 
(Page-McCaw et al., 2007). 
MMPs continue to be discovered. Highly specialized 
MMPs such as enamelysin, found only in the embryonic 
tooth enamel may have corresponding undiscovered 
counterparts in other tissues or organs. The human 
genome project will no doubt uncover further examples. A 
great deal still remains to be learned about the MMPs 
and their inhibition. We know almost nothing about the 
natural substrates of the MMPs in vivo, about how the 
cell senses and regulates the level of enzymes and 
inhibitors out in the matrix, and about the ability of the cell 
to substitute one enzyme for another in knockouts. 
Attention will no doubt focus on ways to regulate the 
activities through gene manipulation and through specific 
inhibitors of enzyme expression or activity. 
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